Top Markets
Coin of the day
ATyr Pharma, Inc. ATyr Pharma, Inc.

ATyr Pharma, Inc.

ATYR
Classement en actions #25453
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego,... aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
Prix de l'action
$0.5049
Dernière synchronisation: 2026-08-20
Capitalisation boursière
$49.51M
Changement (1 jour)
-5.24%
Changement (1 an)
-89.80%
Pays
US
Échange ATyr Pharma, Inc. (ATYR)

Catégorie

Revenus pour ATyr Pharma, Inc. (ATYR)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de ATyr Pharma, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour ATyr Pharma, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
$12.62B -
US
$6.02B -
NL
$15.70B -
AU
- -
CH
$2.23B -
US